Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.
Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.